Vutrisiran improved mortality and recurrent CV risks independent of disease severity and improved several other endpoints for ...

The European Commission has approved BridgeBio's acoramidis for life-threatening heart disorder transthyretin amyloidosis cardiomyopathy (ATTR-CM), setting up a market clash with Pfizer.

The labelling puts it in direct contention with Pfizer's blockbuster Vyndamax/Vyndaqel/Vynmac franchise – based on tafamidis – which has been approved for ATTR-CM since 2019 and is also used ...

The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...

The distinct proteomic profiles they identified suggest that patients with hereditary ATTR-CM may respond better to targeted therapy ... may have worse outcomes but also respond better to Pfizer ...

AI tools that analyze echocardiograms and electrocardiograms can identify those at higher risk of heart disease-related death, a study at the ACC meeting showed.

Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved ...

Pharma presented results showing statistically significant improvements in clinical outcomes as compared to placebo for time ...

Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...

This decision comes after a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial showcased promising results, including a notable reduction in cardiovascular-related hospitalizations ...

1 ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy resulting in heart failure. Alexion, AstraZeneca Rare Disease will be responsible for all ...